Tumor microenvironment promotes breast cancer chemoresistance Umar MehrajAbid Hamid DarManzoor A. Mir Review Article 09 January 2021 Pages: 147 - 158
Disulfiram: a novel repurposed drug for cancer therapy Chen LuXinyan LiXiao Zhang Review Article 10 January 2021 Pages: 159 - 172
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid Milene VolpatoNicola IngramMark A Hull Original Article Open access 11 October 2020 Pages: 173 - 184
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types Nadia TerranovaMendel JansenBart S. Hendriks Original Article Open access 04 November 2020 Pages: 185 - 196
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors Timothy CrookAndrew GayaDadasaheb Akolkar Original Article Open access 10 November 2020 Pages: 197 - 205
PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1 Shuo YuYang LiLan Yang Original Article 21 November 2020 Pages: 207 - 215
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma Haofeng LuLin ZhouYufeng Yuan Original Article 23 November 2020 Pages: 217 - 228
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients Nastja LunarMarie-Christine Etienne-GrimaldiAntonin Schmitt Original Article 02 January 2021 Pages: 229 - 239
Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers Naveed ShaikRobert R. LaBadieGeoffrey Chan Original Article Open access 03 January 2021 Pages: 241 - 250
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer Akira YamagataToshihide YokoyamaTadashi Ishida Original Article 04 January 2021 Pages: 251 - 258
Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair Gloria CinieroAhmed H. ElmenoufyLars Petter Jordheim Original Article 05 January 2021 Pages: 259 - 267
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors R. B. VerheijenT. T. van DuijlA. D. R. Huitema Original Article 23 January 2021 Pages: 269 - 276
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane Maria SpiliotakiGalatea KallergiVassilis Georgoulias Original Article 29 January 2021 Pages: 277 - 287
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review Malvi SavaniKatti WoernerKeith M. Skubitz Short Communication 03 January 2021 Pages: 289 - 294